Skip to main content
Top
Literature
3.
go back to reference Cianfrocca M, Lee S, Von Roenn J, Tulpule A, Dezube BJ, Aboulafia DM, et al. Randomized trial of paclitaxel versus pegylated liposomal doxorubicin for advanced human immunodeficiency virus-associated Kaposi sarcoma: evidence of symptom palliation from chemotherapy. Cancer. 2010;116(16):3969–77. https://doi.org/10.1002/cncr.25362 PMID: 20564162; PMCID: PMC3157242.CrossRefPubMed Cianfrocca M, Lee S, Von Roenn J, Tulpule A, Dezube BJ, Aboulafia DM, et al. Randomized trial of paclitaxel versus pegylated liposomal doxorubicin for advanced human immunodeficiency virus-associated Kaposi sarcoma: evidence of symptom palliation from chemotherapy. Cancer. 2010;116(16):3969–77. https://​doi.​org/​10.​1002/​cncr.​25362 PMID: 20564162; PMCID: PMC3157242.CrossRefPubMed
Metadata
Title
Evaluation of treatments for HIV-associated Kaposi sarcoma in Africa
Authors
Susan E. Krown
Margaret Z. Borok
Publication date
01-12-2021
Publisher
BioMed Central
Published in
Infectious Agents and Cancer / Issue 1/2021
Electronic ISSN: 1750-9378
DOI
https://doi.org/10.1186/s13027-021-00364-5

Other articles of this Issue 1/2021

Infectious Agents and Cancer 1/2021 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine